A 52-year-old man with moderate persistent asthma has been on inhaled beclomethasone dipropionate 200 µg twice daily for 2 years. On routine monitoring, he is found to have a reduction in bone mineral density. Which is the most common systemic adverse effect of long-term inhaled corticosteroid use that accounts for his findings?

Explanation

## Most Common Systemic Adverse Effect of Long-Term Inhaled Corticosteroids **Key Point:** Osteoporosis is the most common and clinically significant systemic adverse effect of long-term inhaled corticosteroid use, particularly in postmenopausal women and older adults. ### Mechanism of ICS-Induced Bone Loss 1. **Direct effect on osteoblasts:** Corticosteroids inhibit bone formation and increase osteoclast activity 2. **Calcium malabsorption:** Reduced intestinal calcium absorption 3. **Increased renal calcium loss:** Enhanced urinary calcium excretion 4. **Hypogonadism:** Reduced sex hormone production (secondary effect) 5. **Systemic absorption:** Even "inhaled" ICS achieve measurable systemic levels, especially at higher doses ### Dose-Dependent Risk | Dose Category | Systemic Effect Risk | |---------------|---------------------| | **Low-dose ICS** (<400 µg/day fluticasone equivalent) | Minimal systemic absorption; bone loss <1%/year | | **Medium-dose ICS** (400–800 µg/day) | Modest systemic absorption; bone loss 1–2%/year | | **High-dose ICS** (>800 µg/day) | Significant systemic absorption; bone loss >2%/year | **High-Yield:** The patient in the vignette is on 400 µg/day beclomethasone (equivalent to ~200 µg fluticasone), which is in the medium-dose range — systemic effects including bone loss are expected. ### Clinical Management - **Baseline DEXA scan:** Recommended for all patients on long-term ICS, especially those >50 years or with risk factors - **Calcium + Vitamin D supplementation:** 1000–1200 mg Ca²⁺ and 800–1000 IU vitamin D daily - **Weight-bearing exercise:** Helps preserve bone density - **Bisphosphonates:** Consider if T-score < −1.5 or if fracture risk is high - **Dose optimization:** Use lowest effective ICS dose **Clinical Pearl:** Bone loss from ICS is most rapid in the first 6–12 months of therapy; the rate of loss plateaus thereafter. Early intervention with calcium, vitamin D, and exercise is crucial. ### Why Other Systemic Effects Are Less Common | Effect | Frequency | Notes | |--------|-----------|-------| | **Osteoporosis** | Most common | Occurs in >10% of long-term ICS users | | **Adrenal suppression** | Rare at low–medium doses | Only with high-dose ICS (>1600 µg/day fluticasone equivalent) | | **Hyperglycemia** | Uncommon | Occurs mainly with systemic corticosteroids, not typical of ICS | | **Hypertension** | Rare | Not a typical systemic effect of ICS | **Mnemonic:** **SCARE** — Systemic effects of long-term ICS: - **S**uppression (adrenal) — rare at low–medium doses - **C**ataracts — rare - **A**trophy (skin) — rare, local effect - **R**isk of infection — minimal - **E**ndocrine (osteoporosis) — MOST COMMON [cite:Harrison 21e Ch 298; KD Tripathi 8e Ch 34]